Immunology

People living with immune-mediated inflammatory diseases can be affected for the rest of their lives, yet the impact of these conditions is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.

We’ve always been innovative in our science, finding new and more effective ways to transform the course of immune-mediated inflammatory diseases and calm the inner battle waging within patients’ bodies.

Since the advent of targeted biologic therapy over 35 years ago, we developed the first licensed monoclonal antibody to act directly on the immune system, providing patients with an unprecedented level of efficacy and symptomatic relief.¹

We remain committed to developing better therapies with the goal of stopping or even curing immune-mediated inflammatory diseases, especially where significant unmet needs persist.

Our commitment to immune-mediated inflammatory diseases goes beyond our medicines. We support patients through collaborations with patient advocacy organisations.

We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.